BCPC BALCHEM CORP

Q3 2025 10-Q
Filed: Oct 21, 2025Period ending Sep 30, 2025
Health Care
Chemicals & Allied ProductsSEC EDGAR

BALCHEM CORP (BCPC) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 21, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • New anti-dumping risk: EU provisional duties 95.4%-120.8% on Chinese choline chloride imports, effective July 1, 2025, final duties proposed 90.0%-115.9%
  • Regulatory risk update: EU anti-dumping measures on choline chloride may restrict market access, investigation initiated October 2024 with final measures expected by end 2025
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$268M

+11.5% YoY +4.7% QoQ

Net Income

$40M

+19.1% YoY +5.3% QoQ

Gross Margin

35.7%

+10bp YoY -77bp QoQ

Operating Margin

20.4%

+40bp YoY +26bp QoQ

Net Margin

15.1%

+96bp YoY +7bp QoQ

ROE

3.1%

Total Assets

$1.7B

EPS (Diluted)

$1.24

+20.4% YoY +6.0% QoQ

Operating Cash Flow

$66M

+27.8% YoY +38.8% QoQ

Source: XBRL data from BALCHEM CORP Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on BALCHEM CORP

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.